Core Viewpoint - Hims & Hers (NYSE:HIMS) shares are experiencing a significant decline of 16% in after-hours trading due to coordinated actions by two federal agencies targeting its compounded weight-loss drugs [1] Company Summary - Hims & Hers is facing regulatory scrutiny as two federal agencies have taken coordinated actions against its compounded weight-loss drugs, leading to a sharp drop in its stock price [1]